Letter to the editor in response to “Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy”
Indian Journal of Ophthalmology · 2024
DOI: 10.4103/ijo.ijo_3022_23 ↗Kurz gefasst
Leserbrief in der Zeitschrift Indian Journal of Ophthalmology, 2024. Verfasst von Shishir Verghese und 2 weiteren Autor:innen. Beteiligte Einrichtung: Consultant Vitreoretinal Surgeon, Vitreoretinal Services, Amita Eye Care, Tiruvalla, Kerala, India. Hauptthemen laut MEDLINE: Intravitreal Injections, Central Serous Chorioretinopathy, Rifampin, Vascular Endothelial Growth Factor A. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Dear Editor, We read the interesting article “Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy” by Sandeep K et al.[1] published in Oct 2023 issue. Authors concluded that intravitreal antivascular endothelial growth factor (anti-VEGF) therapy shows a faster resolution of subretinal fluid in central serous chorioretinopathy (CSC), and also propranolol and rifampicin could be cost-effective treatments for CSC. The study is appealing; however, it has various limitations that require discussion. In the “Introduction” section, the authors have mentioned anti-VEGF injection as one of the mainstay treatments in CSC. However, the role of anti-VEGF in acute as well as chronic CSC is debatable with conflicting reports.[2] Although the role of anti-VEGF is well defined in CSC complicated by secondary choroidal neovascularization[2], various studies have shown that anti-VEGF therapy offers no additional advantage in acute CSC in terms of best-corrected visual acuity (BCVA) as well as central macular thickness (CMT) when compared with observation alone.[3,4] In the “Methods” section, the authors have not clarified whether the patients included in the study had acute or chronic CSC. The final outcomes including BCVA, CMT and contrast sensitivity are known to be affected by the chronicity or duration of the disease.[2] Assuming all the cases were of acute CSC (considering the complete resolution in 100% of cases), a major limitation of this study was not to include a control arm where cases should had been kept under observation. In acute CSC, 90–95% of cases resolve spontaneously with an average resolution time of 3–4 months, with most eyes achieving their initial BCVA.[5] Hence, in the absence of a control arm, it is imprecise to comment on whether the three treatment modalities provided any actual benefit on the resolution of the disease in the acute phase. Also, the methodology used for the result analysis is very simple. In this type of comparative study, authors could have used inferential analysis rather than descriptive analysis. Though the authors have described statistically significant improvement in BCVA, they have not mentioned which test was used to establish the statistical significance. The authors could have performed the intergroup comparison to find out whether there was any statistically significant difference in the final outcomes of three treatment arms. Financial support and sponsorship: Nil. Conflicts of interest: There are no conflicts of interest.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Consultant Vitreoretinal Surgeon, Vitreoretinal Services, Amita Eye Care, Tiruvalla, Kerala, India.
- Consultant Vitreoretinal Surgeon, Vitreoretinal Services, Drishtipunj Eye Hospital, Danapur, Bihar, India.
- Senior Medical Officer, Vitreoretinal Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore, Tamil Nadu, India.
Zitieren
APA
Verghese, S., Ranjan, R., & Manayath, G. J. (2024). Letter to the editor in response to “Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy”. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_3022_23
Vancouver
Verghese S, Ranjan R, Manayath GJ. Letter to the editor in response to “Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy”. Indian Journal of Ophthalmology. 2024. doi:10.4103/ijo.ijo_3022_23
BibTeX
@article{Verghese2024,
author = {Verghese, Shishir and Ranjan, Ratnesh and Manayath, George J},
title = {Letter to the editor in response to “Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy”},
journal = {Indian Journal of Ophthalmology},
year = {2024},
doi = {10.4103/ijo.ijo_3022_23}
}
EUVIMED